Literature DB >> 1992998

Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater.

L Dominioni1, R Dionigi, M Zanello, M Chiaranda, R Dionigi, A Acquarolo, A Ballabio, C Sguotti.   

Abstract

Sixty-two consecutive septic surgical patients receiving standard multimodal intensive care unit treatment who developed a sepsis score of 20 or greater (day 0) were randomized to receive 0.4 g/kg of either intravenous IgG (29 patients) or human albumin (controls; 33 patients), repeated on days +1 and +5, in a prospective, double-blind, multicenter study. The two groups were similar in age, initial sepsis scores, and acute physiology and chronic health evaluation II score. A significantly lower mortality was recorded in the IgG-treated group (38%) than in controls (67%). Septic shock was the cause of death in 7% of IgG-treated patients and in 33% of controls. The results of this study indicate that high-dose IgG improves survival and decreases death from septic shock in surgical patients with a sepsis score of 20 or greater.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1992998     DOI: 10.1001/archsurg.1991.01410260126018

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  15 in total

1.  The effects of IgM-enriched immunoglobulin preparations in patients with severe sepsis: another point of view.

Authors:  Stylianos Karatzas; Eleni Boutzouka; Kyriaki Venetsanou; Pavlos Myrianthefs; George Fildisis; George Baltopoulos
Journal:  Crit Care       Date:  2002-12       Impact factor: 9.097

2.  Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product.

Authors:  M Trautmann; T K Held; M Susa; M A Karajan; A Wulf; A S Cross; R Marre
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

Review 3.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

Review 4.  Sepsis and septic shock. II. Treatment.

Authors:  J Mayer; R Hajek; J Vorlicek; M Tomiska
Journal:  Support Care Cancer       Date:  1995-03       Impact factor: 3.603

5.  Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery.

Authors:  G Pilz; S Kääb; E Kreuzer; K Werdan
Journal:  Infection       Date:  1994 Jan-Feb       Impact factor: 3.553

Review 6.  Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock.

Authors:  Marissa M Alejandria; Mary Ann D Lansang; Leonila F Dans; Jacinto Blas Mantaring
Journal:  Cochrane Database Syst Rev       Date:  2013-09-16

Review 7.  Polyclonal intravenous immune globulin for prevention and treatment of infections in critically ill patients.

Authors:  A Cometta; J D Baumgartner; M P Glauser
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

8.  Prognostic scores and design of clinical studies.

Authors:  C Ohmann
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

9.  Polyclonal intravenous immunoglobulin for the prophylaxis and treatment of infection in critically ill adults.

Authors:  Kevin B Laupland
Journal:  Can J Infect Dis       Date:  2002-03

10.  Granulocyte macrophage colony-stimulating factor improves survival in two models of gut-derived sepsis by improving gut barrier function and modulating bacterial clearance.

Authors:  R Gennari; J W Alexander; L Gianotti; T Eaves-Pyles; S Hartmann
Journal:  Ann Surg       Date:  1994-07       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.